New approaches in the treatment and rehabilitation of ......were used to record patients’...

18 REGUMED Institut für Regulative Medizin, 82166 Gräfelfing • RTI Volume 26 • May 2002

New approaches in the treatment and rehabilitation

of bronchial asthma patients

(combining bioresonance therapy and Detensor therapy)

Professor Dr. med. Olga V. Balakireva, I. V. Netschay

*, Moscow

“MEDART Policura” Medical Centre

INTRODUCTION

Chronic obstructive bronchitis (COB) and bron-

chial asthma (BA) today represent a considerable

problem for modern medicine (1). Relevant publi-

cations reveal that, in the last 10 years, the inci-

dence of chronic obstructive pulmonary disease

(COPD) has grown steadily. Treatment with drugs

is not always effective and is frequently accompa-

nied by complications. Complications associated

with COPD, such as obstructive emphysema and

respiratory insufficiency, are caused, not least, by

dysfunction of the inspiratory muscles and the

vertebral column (2, 3, 4). Observations revealed

that the vertebral column was deformed in 76 % of

bronchial asthma patients (fig. 1). Inspiratory mus-

cle fatigue develops as the muscle system re-

sponsible for breathing is overstrained through

bronchial obstruction and emphysema (5, 6, 7).

When treating bronchial asthma, therapy is gradu-

ally intensified. Patients, whose asthma cannot be

controlled adequately with bronchodilators, are

given corticosteroids to inhale as well as receiving

basic therapy (8). Due to the likelihood that pa-

tients do not correctly master the technique of in-

haling and do not adhere strictly to the instruc-

tions, the dose actually received by the patient

does not always equate to the dose required to con-

trol the asthma symptoms (9). Complication such

as candidosis of the oral cavity and dysphonia oc-

cur if excessive quantities of corticosteroids are

inhaled in a single dose. If inhalational therapy

with corticosteroids proves ineffective, peroral

glucocorticoids, which have a systemic effect, are

included in the treatment programme. There has

long been a need in this connection to develop new

methods of treatment aimed at restoring the func-

tional performance of the body (10, 11, 12). Bio-

resonance therapy (BRT) combined with Detensor

therapy – two new trends in healing and preventive

medicine – currently represent just such an at-

tractive and promising method for treating bron-

chial asthma and its accompanying complication of

inspiratory muscle fatigue (13, 14, 15, 16). BRT

devices work with the human body’s oscillations

based on the principle of induction. As oscillations

emitted by the patient take the form of electromag-

netic oscillations, they can be transmitted by leads.

Oscillations are picked up from the patient using

electrodes, from where they are fed into the de-

vice via a lead. They are converted into oscillations

with reverse polarity in an electronic precision

module and fed back to the patient as amplified

information via a second lead. As a result, the

pathological information is eliminated or partially

suppressed (17, 18). In our investigations BRT

was carried out using the BICOM device developed

by the Regumed Institute in Germany. Treatment

was based on an oscillation model of the patient in

the BICOM device. The device inverts the patholog-

ical oscillation model and transmits it back to the

patient in this inverted form. This process is re-

peated at fractions of a second with the pathologi-

cal oscillations being suppressed and obliterated so

that gradually physiological dynamic balance is

restored. The BICOM device does not employ any

artificially generated frequencies or currents. BRT

is particularly effective in those cases where tradi-

tional methods are unable to achieve a therapeutic

result. It brings together treatment methods such as

Colloquium staged by the International Medical Working Group BICOM Resonance Therapy and BICOM Resonanz-

Therapie-Gesellschaft from 3 to 5 May 2002 in Fulda

www.bioresonance.com

REGUMED Institut für Regulative Medizin, 82166 Gräfelfing • RTI Volume 26 • May 2002 19

acupuncture, Voll’s electro-acupuncture, ho-

meopathy, nosode therapy, isotherapy without ac-

tually replacing any one of them (19). To correct

inspiratory muscle fatigue we employed Prof K. L.

Kienlein’s Detensor method (Germany, 1978),

which is based on the physiological relief and sus-

tained straightening of the spinal column. Tab. 1

shows the effectiveness of the Detensor system in

restoring the functional capacity of the inspiratory

muscles in patients with inspiratory muscle fatigue,

determined using physical methods.

The dynamics of the functional capacity of the

inspiratory muscles in patients with inspiratory

muscle fatigue is shown in tab. 2.

OBJECTIVE AND APPROACH

The aim of our investigation was to prove the ef-

fectiveness of the complex method by which BRT

and Detensor therapy are combined to treat pa-

tients with moderately severe bronchial asthma and

inspiratory muscle fatigue.

The following tasks were formulated to achieve

our desired goal:

1. investigation of the effectiveness of the treat-

ment complex (BRT and Detensor therapy) on

patients with moderately severe bronchial asth-

ma and inspiratory muscle fatigue based on

clinical symptoms.

2. research into the way the treatment complex

works on the functional state of bronchial per-

meability.

To complete these tasks 296 outpatients with

moderately severe bronchial asthma were investi-

gated. They had previously received medium-sized

doses of inhalant corticosteroids combined with

various classes of broncholytics and short-acting

powerful beta2 agonists. Tab. 3 indicates the clini-

cal characteristics of the groups.

The patients were divided into 2 groups: 280

people formed the test group and 16 the control

group, in which the BRT + Detensor therapy treat-

ment complex was not used, but the customary

course of drug treatment for bronchial asthma ex-

acerbation was administered. When external res-

piratory function was examined, all patients dis-

played a high degree of obstruction and air over-

load. Further criteria for inclusion in the study

were daily symptoms, night-time symptoms occur-

ring more than once a week, values for forced ex-

piratory volume in 1 second (FEV1) and peak ex-

piratory flow between 60 % and 80 % of that re-

quired, with over 30 % variability and over 15 %

reversibility. Documentary evidence of the diagno-

sis of bronchial asthma was provided and the se-

verity of the disorder was assessed in line with the

recommendations of the Global Strategy (19). The

course of treatment consisted of a total of 10 twice

weekly BRT sessions and 30 daily Detensor thera-

py sessions. At the same time, patients also re-

ceived additional basic therapy. Patients in the

control group were also in the exacerbation phase

of their disorder and were therefore offered a short

course of glucocorticoid therapy in view of the fact

that high single doses of glucocorticoids could

not bring the patients’ bronchial permeability un-

der control.

The efficacy of the treatment complex (10 BRT

sessions and 30 Detensor therapy sessions) was

determined based on the results of a clinical func-

tional examination of the patients before and after

complex treatment (BRT and Detensor therapy),

measuring peak flow, recording values of the flow

volume curve with forced expiration and daily

beta2 agonist requirement. Self-assessment forms

were used to record patients’ symptoms, daily re-

quirement of short-acting powerful beta2 agonists

as well as the dynamics of the symptoms occur-

ring during the day and of nightly waking due to an

asthma attack. An improvement in the clinical val-

ues of all the parameters was observed in 89 % of

bronchial asthma patients upon completion of the

treatment complex. An analysis of peak flow

measurements and patients’ diary entries, in which

the number of urgent Ventolin inhalations during

the day and night were recorded, revealed that the

treatment complex was able to bring night-time

symptoms under control and reduce the number of

inhalations of short-acting powerful beta2 agonists.

(In practice, towards the end of treatment, patients

required, on average, no more than one or two in-

halations of Berotek in a 24 hour period). By the

second week, the Berotek requirement had already

dropped by half (fig. 2).

From the third week the average number of in-

halations for patients in the test group was 1–0.5

per day, which matched the results of the patients

in the control group. Towards the end of the fourth

week the number of inhalations in the test group

fell virtually to zero while that of the control group

remained unchanged. Moreover, a positive long-

term effect was observed within the ten weeks fol-

lowing completion of the treatment (fig. 3).

Fig. 4 shows the variability of the parameters

for bronchial permeability, measured by the aver-



age daily coefficient of variation of the peak expir-

atory rate.

The respiratory mechanism was monitored

using a Flowscreen device (Erich Jäger, Germany).

Peak values for inspiratory and expiratory flow

were obtained by examining the flow volume

curves for forced expiration and inhalation. The 12

second standard manoeuvre was used to determine

the MVV value. The results obtained were ex-

pressed as a percentage of the normal value. The

results were analysed statistically based on Wil-

coxon’s non-parametric criteria and according to

the variational statistical method using Student’s t-

criteria. The dynamics of external respiratory func-

tion in bronchial asthma patients is displayed in

table 4.

As can be seen from the table, the patients in

the test group and the control group were initially

in a functionally adverse condition which had de-

veloped as a result of severe obstruction combined

with air overload, i. e. in an exacerbation phase of

bronchial asthma. A significant increase in the pa-

rameters of the flow volume curve was observed

after 10 treatment sessions with the complex.

External respiratory function values were com-

pared with the data from the control group in

which the patients had undergone a short 5-week

course of glucocorticoids with the preparation

gradually being eliminated. When lung vital capac-

ity, peak inspiratory and expiratory flow, forced

expiratory volume in 1 second and permeability of

the large, intermediate and small bronchi were

examined, a significant increase in values was

observed in the patients in the control group

[Translator’s note: sic], similar to those of the con-

trol group, but with the virtual suspension of drug

treatment. Thus the value for forced expiratory

volume in 1 second rose from 48 % at the start of

treatment to 72 % within the first two weeks and to

92 % within the following two weeks. The increase

amounted to 20 % for the large bronchi and 17 %

for the small. The effect was significant, positive

and sustained, i. e. it lasted 8 months.

The overall assessment of the effectiveness of

combined treatment with BRT and the Detensor

system was carried out both by the patients them-

selves and the attending doctor (fig. 5).

CONCLUSIONS

The results of the investigation enable the follow-

ing conclusions to be drawn:

1. The treatment complex based on BRT and the

Detensor system is an ideal treatment method

for bronchial asthma patients from the point of

view of efficacy and reliability.

2. BRT allows the body’s intoxication to be re-

duced. It increases the body’s reserves and im-

munity by acting on the inflammatory process.

3. Detensor therapy allows the mobile sections of

the spinal column to be released easily and

without complications, the shape of the spinal

column to be restored, and the strength and

reserves of the inspiratory muscles to be regen-

erated.

4. Use of the treatment complex ensures bronchial

permeability and daily variability is controlled

in a stable manner.

5. The healing process associated with the treat-

ment complex has no side effects.

LITERATURE

1. Отчет о международном соглашении по ди-

агностике и лечению бронхиальной астмы.

Национальный институт кардиологии,

пульмонологии и гематологии.

Национальные институты

здравоохранения – Бетеса, Мериленд, 1992.

2. Александрова Н. П., Голубева Е. В.,

Миняев В. П., «Взаимодействие наружных

межреберных мышц и диафрагмы при

развитии утомления дыхательной

мускулатуры» – Актуальные вопросы

медицины-М., 1993. – p. 114-122.

3. Туранова З. П., Утомление

диафрагмальной мышцы-диагностика и

лечение. – Tер. Aрхив – 1994. – № 8. – p. 77-

80.

4. Poussos C., Macklem P. T., Inspiratory muscle

fatigue – Handbook of Physiology. The Respi-

ratory System. – Washington, 1986. – Vol. 3,

Pt. 2. – p. 511-527.

5. Айсанов З. Р., Утомление дыхательных

мышц: Вопросы диагностики и лечения:

Дис. … канд. мед. наук. – М., 1987.

6. Бичев А. А., Чучалин А. Г., Механизмы

утомления дыхательной мускулатуры –

Пульмонология – 1992ю – № 4 – p. 82-89.

7. Чучалин А. Г., Айсанов З. П., Нарушение

функции дыхательных мышц при хрони-

ческих обструктивных заболеваниях лег-

ких – Тер. Aрх. – 1988 – № 8 – p. 126-132.



8. International consensus report on the diagnosis

and treatment of asthma – Eur. Respir. J. –

1992 – Vol. 5 – p. 601-642.

9. Haahtela T. et al., Effects of reducing or dis-

continuing inhaled budisonide in patients with

mild asthma – N. Engl. J. Med. – 1994 – Vol.

331, # 11 – p. 700-705.

10. Чучалин А. Г., Симпозиум «Новый подход

к лечению бронхиальной астмы», Тезисы

докладов – М., 1997 – p. 6

11. Овчаренко С. И., Шеянов М. В., Маколкин

В. И., Факторы риска и пути предотвраще-

ния ранних неблагоприятных исходов

бронхиальной астмы – Тер. Арх. – 1998 –

№ 3 – p. 18-22.

12. Дуков Л. Г., Борохов А. И., Диагностика и

лечение болезней органов дыхания – Смо-

ленск, Русич, 1996.

13. Биорезонансная и мультирезонансная тера-

пия, Сборник трудов «Имедис», М. 1996 С.

9-27. (8) И. Л. Блинков, Ю. В. Готовский

Структурно-резонансная терапия, М. –

1998.

14. Лихарев В. А., Основы биорезонансной те-

рапии (Методические рекомендации), М. –

1996.

15. Кинляйн К. Л., Штраус Й., Романов А.

И., Балакирева О. В., Лечение заболеваний

позвоночника с применением

многоцелевой системы «ДЕТЕНЗОР» –

Клин. Bести. – 1996. – № 1 – p. 64

16. Kienlein K. L., Die Detensor-Methode. [The

Detensor method]. Published privately. – Roe-

thenbach, 1990. – p. 3-20.

17. Франц Морелль, Mora-терапия, Германия –

1994.

18. BICOM Computer-Therapie-Handbuch [BICOM

computer therapy manual] – Brügemann GmbH,

1994.

19. Global Initiative for Asthma. Global Strategy

for Asthma Management and Prevention,

NHLB/WHO Workshop Report. 1993 – Be-

thesda, 1995 – p. 1-175.

20. Balakirewa Olga V., Aktiv und gesund: frei

von Rückenschmerzen durch die Detensor-

Methode. [Active and healthy: free from back

pain through the Detensor method] Olga V.

Balakirewa, Alexej V. Kapustin. – 1st Ed. –

Baunach: Deutscher Spurbuchverlag, 1999,

ISBN 3-88778-229-1

21. Kapustin, A. V., Balakirewa, O. V., Rücken-

schmerzen. Ein neues Verfahren zur Behand-

lung und Prophylaxe bei Erwachsenen und

Kindern. [Back pain. A new method of treat-

ment and prevention for adults and children].

To be published.



Table 1

Physical methods of investigating inspiratory muscle fatigue

Method Test group

n=280 Control group

n=16 before treatment after treatment before treatment after treatment 1. Checking relative displacement of thorax and abdo-men (one hand on the patient’s chest, the other on the abdomen)

asynchronous breathing

symptom disappears

asynchronous breathing

symptom remains

2. Palpating the ab-domen to determine possible increase in intraabdominal pressure on inhaling

intraabdominal pressure increases, isolated contrac-tions of abdominal muscles

pressure does not increase, abdominal muscles do not contract

intraabdominal pressure increases, isolated contrac-tions of abdominal muscles

maintained

Table 2

Dynamics of external respiratory function

Parameter Test group Kontrollgruppe Initial

state after

1 procedure after

10 procedures Initial state

after 1 procedure

MVV 56.4 ± 5.4 63.0 ± 8.9 66.5 ± 8.7 48.5 ± 5.8 49.1 ± 5.2

VC 74.1 ± 7.5 88.1 ± 9.6 93.2 ± 8.8 82.4 ± 9.8 84.1 ± 7.8

IC 99.1 ± 9.8 90.1 ± 9.2 90.0 ± 8.9 75.6 ± 8.4 76.7 ± 7.9

ERV 56.1 ± 9.5 59.2 ± 5.2 51.2 ± 4.8 62.9 ± 9.6 66.2 ± 9.5

FVC 67.8 ± 8.9 77.7 ± 8.3 83.7 ± 8.0 65.2 ± 6.2 62.4 ± 6.2

FEV1 42.6 ± 4.1 48.8 ± 4.6 57.5 ± 5.7 53.4 ± 5.3 56.2 ± 5.8

PEF 25.2 ± 2.4 35.4 ± 3.2 32.6 ± 8.8 27.8 ± 8.4 31.4 ± 4.2

MEF 50 27.3 ± 3.1 27.2 ± 2.1 23.8 ± 2.3 34.5 ± 3.2 36.4 ± 3.2

MEF 25 26.7 ± 2.7 28.5 ± 2.8 26.7 ± 2.4 30.4 ± 2.9 32.6 ± 2.9

MMEF 25/75 24.3 ± 2.2 26.5 ± 3.4 26.4 ± 2.5 41.4 ± 4.0 40.4 ± 3.9

FIV 1 42.5 ± 5.3 56.4 ± 5.2 63.5 ± 6.1 44.9 ± 7.6 48.7 ± 8.2

Rocc 110.0 ± 12.1 84.0 ± 8.2 68.2 ± 6.9 104.0 ± 12.4 102.0 ± 13.4



Table 3

Clinical description of patient groups

Group Nosology Number of patients

observed

Sex Age Length of illness

Steroid depend-

ency male female years weeks Test group n = 280

Bronchial asthma

280

160

120

Average

39.5 (20 to 59)

11 (2-40)

220 1000-1600 Budesonide

or 500-800

Fluticazon propionate

Control group n = 16

Bronchial asthma

16

10

6

Average

39.5 (20 to 59)

11 (2-40)

16 1000-1600 Budesonide

or 500-800

Fluticazon propionate

Table 4

Dynamics of external respiratory function (as a percentage of normal values) in patients with moderately severe bronchial asthma

Parameter Test group

n = 280 Control group

n = 16 (short course of glucocorticoids)

before treatment after treatment before treatment after treatment FVC 103.5 ± 4.5 117.2 ± 3.7 105.4 ± 4.4 120.8 ± 4.5 FEV1 48.0 ± 6.7 92.0+3.5 48.2 ± 6.1 108.3 ± 8.4 FEF 25-75 48.2 ± 10.8 71.0 ± 6.1 45.6 ± 8.5 78.8 ± 6.9 FEF 25 60.3 ± 8.4 79.9 ± 6.3 45.0 ± 6.7 99.3 ± 5.6 FEF 50 40.3 ± 10.0 60.1 ± 6.3 32.9+8.4 84.9 ± 7.9 FEF 75 28.8 ± 12.2 45.7 ± 5.2 28.0 ± 8.7 64.0 ± 6.2 PEF1 68.2 ± 3.3 78.7 ± 5.3 65.0 ± 2.6 99.2 ± 4.1 VC 98.7 ± 7.0 99.7 ± 4.9 99.9 ± 5.5 113.2 ± 5.1 Rocc 110.0 ± 12.1 94.0 ± 8.0 104.0 ± 12.4 83.0 ± 13.4



Before

Detensor therapy

After

Detensor therapy

After traction of the spinal column with Detensor therapy, the following was ob-served:

thoracic hyperkyphosis reduced length of thoracic kyphosis normalised abdominal and intrapleural pressure reduced thoracic and abdominal breathing synchronised

Figure 1



Dynamics of inhalations of

short-acting powerful beta2 agonists required

in the course of treatment

0

1

2

3

4

5

6

7

8

9

0 2

woche

5

woche

10

woche

Versuchsgruppe

Kontrollgruppe(Kurzer GKS-Behandlunskurs)

Figure 2

Average number of adrenergic-free days for bronchial asthma patients following

combined BRT and Detensor therapy

0

1

2

3

4

5

6

7

1 2 3 4 5 6 9 10 11

Figure 3

Test group

Control group

(short course of

glucocorticoid

treatment)

Number of days

Weeks after treatment

Week

Test group

Control group

(one week after

short course of

glucocorticoid

treatment)



Variability of peak expiratory rate

0

5

10

15

20

25

30

0 2

woche.

5

woche

10

woche

Versuchsgruppe

Kontrollgruppe(Kurzer GKS-Behandlungskurs)

Figure 4

Assessment of the clinical effect of the treatment complex

by the test director

by the patients

satisfactory

good

excellent

Figure 5

16.5 %

88.9 % 77.8 %

5.5 %

11.1%

Test group

Control group

(short course of

glucocorticoid

treatment)

Week


Date post:	25-May-2020
Category:	Documents
Upload:	others
View:	2 times
Download:	0 times

New approaches in the treatment and rehabilitation of ......were used to record patients’...

Documents